Literature DB >> 12623807

Role of amniotic membrane transplantation for conjunctival reconstruction in ocular-cicatricial pemphigoid.

Stefano Barabino1, Maurizio Rolando, Giorgio Bentivoglio, Cristina Mingari, Sabrina Zanardi, Rosa Bellomo, Giovanni Calabria.   

Abstract

PURPOSE: To evaluate the role and the effectiveness over time of amniotic membrane transplantation (AMT) as a first-step procedure to treat conjunctival reconstruction in late-stage ocular-cicatricial pemphigoid (OCP).
DESIGN: Prospective interventional noncomparative case series. PARTICIPANTS: Nine eyes (9 patients) with advanced OCP.
METHODS: Preoperatively, the ocular surface conditions were evaluated by immunohistochemistry of conjunctival biopsy and impression cytology specimens. The amniotic membrane was obtained during cesarean section from women who were 39 weeks pregnant and seronegative for human immunodeficiency virus, hepatitis B and C, and syphilis; it was processed, histologically tested, and stored at -80 degrees C. After scar tissue was removed, the preserved amniotic membrane was placed over the cornea, the bulbar, and tarsal conjunctiva, and was secured with 8-0 Vicryl sutures to the conjunctival edges and the deep fornices with double-armed 6-0 silk sutures. In 2 cases a double layer of amniotic membrane was transplanted. All patients received immunosuppressive systemic therapy and preservative-free tear substitutes and steroids topically for at least 6 months. During follow-up (average, 48 weeks; range, 28-96 weeks), a new standardized method was used to evaluate the fornix depth, and impression cytology testing was performed and conjunctival inflammation recorded and used as parameters for monitoring disease activity. MAIN OUTCOME MEASURES: Symblepharon, increased inferior fornix depth, presence of conjunctival goblet cells, and the degree of conjunctival inflammation.
RESULTS: The conjunctival surface was free from symblepharon in all subjects for the first 16 weeks. At the week 28 examination, a small area of symblepharon was present in four eyes (44.4%). The depth of the fornix was significantly (P < 0.0001, analysis of variance) improved at weeks 4, 16, and 28. The normal conjunctival epithelium with goblet cells was restored in 6 of 9 eyes (66.7%) at the week 4 examination and in 4 eyes (44.4%) at the week 28 examination. Conjunctival inflammation was clinically but not statistically reduced. The visual acuity improved in 5 subjects.
CONCLUSIONS: AMT can be a first-step procedure for ocular surface reconstruction in OCP, but its effectiveness deteriorates slightly over time.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12623807     DOI: 10.1016/S0161-6420(02)01892-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  14 in total

1.  [Late complications after chemical burns of the ocular surface. Surgical strategies for ocular surface reconstruction].

Authors:  B Bachmann; C Cursiefen
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

2.  Amniotic membrane transplantation for ocular disease: a review of the first 233 cases from the UK user group.

Authors:  Valerie P J Saw; Darwin Minassian; John K G Dart; Andrew Ramsay; Hugo Henderson; Stefan Poniatowski; Ruth M Warwick; Suzanne Cabral
Journal:  Br J Ophthalmol       Date:  2007-02-21       Impact factor: 4.638

3.  The use of impression cytology in the follow-up of severe ocular burns.

Authors:  Jean-Jacques Gicquel; Renaud Navarre; Maria Elena Langman; Alix Coulon; Stephanie Balayre; Serge Milin; Martial Mercie; Alexis Rossignol; Anne Barra; Pierre-Marie Levillain; Jean-Marc Gombert; Paul Dighiero
Journal:  Br J Ophthalmol       Date:  2007-04-30       Impact factor: 4.638

Review 4.  Graft failure: II. Ocular surface complications.

Authors:  Samar A Al-Swailem
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

5.  Amniotic membrane as a carrier for lacrimal gland acinar cells.

Authors:  S Schrader; Th Wedel; C Kremling; H Laqua; G Geerling
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-06-12       Impact factor: 3.117

Review 6.  [Mucous membrane pemphigoid with ocular involvement. Part II: therapy].

Authors:  T Meyer-ter-Vehn; E Schmidt; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-04       Impact factor: 1.059

7.  Rapid bioprinting of conjunctival stem cell micro-constructs for subconjunctival ocular injection.

Authors:  Zheng Zhong; Xiaoqian Deng; Pengrui Wang; Claire Yu; Wisarut Kiratitanaporn; Xiaokang Wu; Jacob Schimelman; Min Tang; Alis Balayan; Emmie Yao; Jing Tian; Luwen Chen; Kang Zhang; Shaochen Chen
Journal:  Biomaterials       Date:  2020-10-23       Impact factor: 12.479

8.  Validation of a fornix depth measurer: a putative tool for the assessment of progressive cicatrising conjunctivitis.

Authors:  Geraint P Williams; Valerie P J Saw; Tariq Saeed; Simon T Evans; Paul Cottrell; S John Curnow; Peter Nightingale; Saaeha Rauz
Journal:  Br J Ophthalmol       Date:  2010-10-17       Impact factor: 4.638

Review 9.  Current concepts of ocular adnexal surgery.

Authors:  Maria Borrelli; Gerd Geerling
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2013-02-27

10.  Treatment strategies in mucous membrane pemphigoid.

Authors:  Ann G Neff; Matthew Turner; Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.